We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

And then when you get diabetic or if you gain weight or have obesity, your GLP-1 levels goes down. So when we use GLP-1 analogs, they are basically biologic drugs that mimic your own hormones that you ...

These statements relate to, among other things, the anticipated benefits and impact of the AI-driven peptide discovery pipeline, the potential for computationally designed GLP-1 analogs to improve ...

These statements relate to, among other things, the anticipated benefits and impact of the AI-driven peptide discovery pipeline, the potential for computationally designed GLP-1 analogs to improve ...

Thanks to this, analogs that function similarly to GLP-1 are used as treatments for patients with type 2 diabetes, who have insufficient insulin secretion. Recently, it has also gained attention ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...